Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
2014 · Nature · 5,183 citations
https://doi.org/10.1038/nature14011
M
Michael S. Gordon
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
571
Papers
27.9K
Citations
72
h-index
230
i10-index
Michael S. Gordon is an academic researcher from Translational Genomics Research Institute. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & CAR-T cell therapy research & Colorectal Cancer Treatments and Studies. The author has an h-index of 72, co-authored 486 publications.
ORCID: 0000-0002-7679-9504Papers by this author
worksSafety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
2016 · Journal of Clinical Oncology · 840 citations
https://doi.org/10.1200/jco.2016.67.9761
Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status
2006 · Journal of Clinical Oncology · 249 citations
https://doi.org/10.1200/jco.2005.05.4221
PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
2020 · Nature Communications · 86 citations
https://doi.org/10.1038/s41467-020-19810-w
Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial
2024 · Nature Medicine · 83 citations
https://doi.org/10.1038/s41591-024-03083-7
Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma
2017 · British Journal of Cancer · 70 citations
https://doi.org/10.1038/bjc.2016.419
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat